Derazantinib hydrochloride is under clinical development by Merck & Co and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Derazantinib hydrochloride’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 25 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 25 Nov 2022 increased Derazantinib hydrochloride’s LoA and PTSR for Hepatocellular Carcinoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Derazantinib hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Derazantinib hydrochloride overview

Deranzantinib hydrchloride (ARQ-087) is under development for the treatment of intrahepatic cholangiocarcinoma (iCCA), adenocarcinoma of the gastroesophageal junction, adrenocortical tumors, advanced solid tumors and urothelial cell carcinoma. The drug candidate is administered orally. ARQ-087 is an inhibitor of pan-fibroblast growth factor receptor (FGFR) and CSF1R. The drug candidate is based on proprietary structure-based drug design technology known as the ArQule Kinase Inhibitor Platform (AKIP).

Merck & Co overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Quick View Derazantinib hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Derazantinib hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Merck & Co
  • Originator: ArQule
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.